Bronchodilators are medications that relax and widen the airways (bronchi and bronchioles) in the lungs, making it easier to breathe. They are commonly used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. Several pharmaceutical companies are involved in the development and production of bronchodilator medications.
Latest Bronchodilators Companies Update
Nov 2023: The European Pharmaceuticals Agency's human pharmaceuticals committee has recommended that GSK, a British company, be approved for its oral medication to treat anemia in patients suffering from myelofibrosis, a bone marrow malignancy. According to a statement from GSK, a decision regarding the marketing authorization of momelotinib is anticipated by early 2024.
Apr 2023: The pharmaceutical company Cipla said it has entered a permanent license deal with Novartis Pharma AG, based in Switzerland, to produce and distribute the type 2 diabetes therapy brands Galvus and Galvus combo starting on January 1, 2026. With the drug's reported sale, Cipla's portfolio in the diabetes care continuum is anticipated to be greatly enhanced. Cipla went on to elaborate on the arrangement, stating that it is contingent upon the fulfillment of several previous requirements. Nonetheless, the business will keep selling and distributing goods under the Galvus name. Galvus is a well-known brand and one of the top names in the Dipeptidyl Peptidase-4 (DPP4) market for oral diabetic medications. With the agreement, Cipla hopes to strengthen its position in India as one of the highest players in the diabetes category.
Bronchodilators Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)